No link between Merck's Gardasil and blood clots, study says

Merck's Gardasil HPV vaccine--FierceBiotech file photo
Merck's Gardasil

Worries over Gardasil's safety are just one of the issues that have hampered uptake of Merck's ($MRK) best-selling vaccine for HPV. But now, a study published in JAMA says patients need not worry about an increased risk of deadly blood clots--a.k.a. venous thromboembolism, or VTE--in the period after vaccination. Researchers in Denmark examined a database of 1,613,798 women, finding that those who received the vaccine averaged 0.126 clots per person per year, compared with a rate of 0.159 clots per person per year in those who did not receive it. More

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.